Linda Cucciniello

Dr. Linda Cucciniello


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2023 in Cancer Treatment Reviews
Verified
Journal Article
Open access
LCLinda Cucciniello
Linda Cucciniello
GGGiovanna Garufi
Giovanna Garufi
RRRossana Di Rienzo
Rossana Di Rienzo
CMClaudia Martinelli
Claudia Martinelli
GPGiuliana Pavone
Giuliana Pavone
Fabio PuglisiFabio Puglisi
Fabio Puglisi
Endocrine therapy is one of the standard adjuvant treatments to reduce the risk of recurrence and mortality in patients with hormone receptor positive early breast cancer. Despite its proven efficacy, ET side effects, which persist over time even if low grade, may deteriorate quality of life. During follow-up visits, emphasis is generally placed on the risk of disease recurrence, while the topic of ET side effects is commonly neglected and discussed only briefly. This could lead to poor adherence to therapy and early treatment discontinuation, resulting in worse survival outcomes. The aim of this review is to provide an overview of the available evidence on the incidence and reporting of ET-related side effects (including vasomotor symptoms, musculoskeletal disorders and genitourinary syndrome of menopause, as well as fatigue, psychological and ocular disorders, dysmetabolic effects and loss of bone density) and of the pharmacological and non-pharmacological strategies available to mitigate symptom burden.

11 December 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
Mattia GaruttiMattia Garutti
Mattia Garutti
CNClaudia Noto
Claudia Noto
BPBrenno Pastò
Brenno Pastò
LCLinda Cucciniello
Linda Cucciniello
MAMassimiliano Alajmo
Massimiliano Alajmo
Fabio PuglisiFabio Puglisi
Fabio Puglisi
Throughout their experience of illness and during the course of treatment, a substantial proportion of cancer patients are prone to develop nutritional and/or metabolic disturbances. Additionally, cancer patients often encounter long-term side effects from therapies, which may lead to impaired digestion, nutrient absorption or bowel motility. Therefore, the preservation and maintenance of an optimal and balanced nutritional status are pivotal to achieving a better prognosis, increasing the tolerance and adherence to cancer therapies and improving the overall quality of life. In this context, personalized nutritional programs are essential for addressing conditions predisposing to weight loss, feeding difficulties, digestion problems and intestinal irregularity, with the goal of promoting adequate nutrient absorption and minimizing the detrimental effects of treatment regimens. The focus of this research is to examine the most common clinical conditions and metabolic changes that cancer patients may experience, including stomatitis, xerostomia, diarrhea, nausea, vomiting, dysphagia, sub-occlusion, dysgeusia, dysosmia, anorexia, and cachexia. Furthermore, we present a pragmatic example of a multidisciplinary workflow that incorporates customized recipes tailored to individual clinical scenarios, all while maintaining the hedonic value of the meals.

24 May 2024 in The Breast
Verified
Journal Article
Open access
LCLinda Cucciniello
Linda Cucciniello
FMFederica Miglietta
Federica Miglietta
VGValentina Guarneri
Valentina Guarneri
Fabio PuglisiFabio Puglisi
Fabio Puglisi
The significant advancements in breast cancer management have led to an increase in the prevalence of breast cancer survivors. Despite their efficacy, these treatments can cause a variable range of side effects, significantly deteriorating the patients' quality of life. Sexual dysfunction, and in particular the genitourinary syndrome of menopause, represent one of the major causes of quality-of-life impairment among breast cancer patients, potentially affecting treatment adherence and compliance. If in the general population, hypoestrogenism-related symptoms are typically managed through systemic or topical estrogen administration, this approach is contraindicated in breast cancer patients for the potential increased risk of disease recurrence, urging the investigation of alternative measures. The aim of this review is to summarize the most up-to-date pharmacological and non-pharmacological interventions, as well as supportive measures, available for the management of sexual dysfunctions in breast cancer patients and survivors.

4 August 2022 in Cancer Treatment Reviews
Verified
Journal Article
Open access
LCLinda Cucciniello
Linda Cucciniello
Lorenzo GerratanaLorenzo Gerratana
Lorenzo Gerratana
Lucia Del MastroLucia Del Mastro
Lucia Del Mastro
Fabio PuglisiFabio Puglisi
Fabio Puglisi
Endocrine therapy represents the gold standard for the adjuvant treatment of luminal-like early breast cancer, but its personalization is still a major point of debate. To define the most appropriate therapeutic strategy, both the patient's menopausal status at the moment of diagnosis and the individual risk of disease recurrence should be taken into account. Five years of therapy with tamoxifen represent the standard of care for low-risk pre/perimenopausal patients, whilst the combination of ovarian suppression with tamoxifen or an aromatase inhibitor should be considered for high-risk patients. Also, to high-risk patients, an extended strategy can be proposed. Postmenopausal patients, instead, should receive an upfront aromatase inhibitor and an extended strategy can be considered for a high risk of disease recurrence. Aim of this review is to set a focus on the major studies investigating the optimal type and duration of adjuvant endocrine therapy and evaluate emerging options.

1 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LCLinda Cucciniello
Linda Cucciniello
Lorenzo GerratanaLorenzo Gerratana
Lorenzo Gerratana
Fabio PuglisiFabio Puglisi
Fabio Puglisi
To date, tissue biopsy still represents the mainstay for tumor diagnosis and molecular characterization